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Background: Complete remission from advanced-stage synchronous double primary (SDP) esophageal and gastric
adenocarcinoma by chemotherapy alone is rare. We report a case of advanced-stage SDP esophageal and gastric
adenocarcinoma in which a complete response to treatment was obtained with S-1 and cis-
diamminedichloroplatinum (CDDP).
Case presentation: The patient was a 74-year-old man referred to our hospital complaining of dysphagia.
Gastrointestinal endoscopy was performed and advanced-stage SDP esophageal and gastric adenocarcinoma
diagnosed. Computed tomography revealed multiple regional lymph node metastases in the mediastinum.
Neoadjuvant chemotherapy with S-1 and CDDP for advanced esophageal and gastric cancer was planned. An
endoscopy following two courses of chemotherapy revealed that the esophageal cancer had been replaced with a
normal mucosal lesion and the gastric tumor with a scar lesion; the results of biopsies of both were negative for
cancer. Computed tomography revealed that the multiple lymph node metastases had disappeared. We diagnosed
a complete response to S-1 and CDDP in advanced-stage SDP esophageal and gastric cancer. The patient is still
alive with no signs of recurrence 22 months after the disappearance of the original tumor and metastatic lesions
without surgical treatment.
Conclusion: These results suggest that complete remission from advanced-stage esophageal and gastric cancer
can be obtained with chemotherapy with S-1 plus CDDP.
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The standard treatment for advanced-stage esophageal
cancer is esophagectomy. Despite advances in surgical
technique, the prognosis of advanced-stage esophageal
cancer is still poor [1]. Additionally, some studies
have reported that double primary cancer in patients
with esophageal cancer has a worse prognosis than a
single malignancy [2,3] and that synchronous double
primary (SDP) cancer has a worse prognosis than
metachronous cancer [4,5]. Several prospective trials* Correspondence: kochi.mitsugu@nihon-u.ac.jp
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reproduction in any medium, provided the orhave demonstrated that neoadjuvant chemotherapy in
conjunction with surgical intervention confers a sur-
vival benefit for locally advanced esophageal cancer [6,7].
Recent chemotherapeutic regimens including S-1 have
produced good clinical responses and survival benefits in
patients with gastric cancer in Japan [8]. Tumor response
to an S-1 regimen in patients with advanced esophageal
adenocarcinoma, however, remains to be elucidated.
Complete remission of advanced-stage SDP esophageal
and gastric adenocarcinoma to chemotherapy is rare. One
such case is reported here.al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 2 Upper-gastrointestinal endoscopy before and after
treatment of upper gastric tumor. (a) In January 2009, initial
upper-gastrointestinal endoscopy disclosed Borrmann type II tumor
measuring 5.0 cm × 4.0 cm in upper gastric tumor. (b) In April 2009,
follow up after first course of chemotherapy with S-1 and cis-
diamminedichloroplatinum, upper-gastrointestinal endoscopy
revealed scar lesion instead of tumor; no further lesions were
identified.
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The patient was a 74-year-old man who had previously
been treated for diabetes, meningitis, hypertension and
hyperglycemia by his family doctor. In October 2009, the
patient was referred to the Department of Digestive Sur-
gery, Nihon University School of Medicine Itabashi Hos-
pital, complaining of dysphagia. An upper-gastrointestinal
endoscopy revealed a mid-esophageal type I tumor measur-
ing 2.5 cm×2.5 cm (Figure 1a) and an upper-gastric type
III tumor measuring 5.0 cm×4.0 cm (Figure 2a). Biopsy
specimens revealed that both tumors were moderately dif-
ferentiated adenocarcinomas. We diagnosed advanced-
stage SDP esophageal and gastric adenocarcinoma. Com-
puted tomography (CT) revealed multiple regional lymph
node metastases in the mediastinum (Figure 3a). Neoadju-
vant chemotherapy with S-1 (Taiho Pharmaceutical, Tokyo,
Japan) and cis-diamminedichloroplatinum (CDDP) was car-
ried out for advanced esophageal and gastric adenocarcin-
oma. S-1 has recently produced good clinical responses and
survival benefits in Japanese patients with gastric and colo-
rectal adenocarcinoma, and hypopharyngeal and laryngeal
squamous cell carcinoma. In this case, S-1 was adminis-
tered orally at a dose of 80 mg/m2 per day for 21 consecu-
tive days followed by a 14-day drug-free interval. Infusional
CDDP was administered at a dose of 60 mg/m2 for 90 min
on day 8. The patient developed only grade 1 gastrointes-
tinal dysfunction in all the course of this chemotherapy. An
endoscopy performed after two courses of chemotherapy
revealed that the esophageal cancer had been replaced with
normal mucosa and the gastric cancer with a scar lesion
(Figures 1b, 2b); the results of the biopsies of both were
negative for cancer lesions. Additionally, CT revealed that
the multiple lymph node metastases had disappeared
(Figure 3b). We diagnosed complete response of advanced-
stage SDP esophageal and gastric adenocarcinoma to S-1
and CDDP as a neoadjuvant chemotherapy, obviating theFigure 1 Upper-gastrointestinal endoscopy before and after
treatment of mid-esophageal tumor upper gastric tumor. (a) In
January 2009, initial upper-gastrointestinal endoscopy disclosed mid-
esophageal type I tumor measuring 2.5 cm × 2.5 cm. (b) In April
2009, follow up after first course of chemotherapy with S-1 and cis-
diamminedichloroplatinum, upper-gastrointestinal endoscopy
revealed scar lesion instead of tumor; no further lesions were
identified.need for surgical treatment. Over the next 4 months, peri-
odic follow-up was performed to determine whether any
further esophageal or gastric lesions had formed. After 4
courses of the S-1 and CDDP chemotherapy regimen, the
patient remains on outpatient 8 cycles adjuvant chemother-
apy with S-1 only at a dose of 80 mg/m2 per day for 28
consecutive days followed by a 14-day drug-free interval
without surgical treatment. A periodically performed
upper-gastrointestinal endoscopy performed in July 2011
revealed no new tumor lesions and CT has revealed no
lymph node metastasis. As of September 2011, the patient
is alive with no signs of recurrence at 22 months after the
disappearance of the original tumors.
Discussion
Several retrospective studies have reported that the
complete response rate of advanced-stage esophageal
cancer to chemotherapy is between 2.0% and 5.6% [9-12].
In contrast, the complete response of advanced-stage gas-
tric cancer to chemotherapy has been reported to be be-
tween 0% and 0.7% [13,14]. A complete response of SDPFigure 3 Computed tomography images before and after
treatment. Initial computed tomography revealed multiple lymph
node metastases around esophagus. (b) Follow-up computed
tomography revealed that multiple lymph node metastases around
esophagus had completely disappeared.
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is rare. Several retrospective studies have reported a
complete response rate of 17% to 36% to chemoradiother-
apy for advanced esophageal cancer [6,7,15]. However,
radiotherapy is not standard therapy for gastric cancers be-
cause there are few cancer of the esophagogastric junction
in Japan. Our results suggest that chemotherapy with S-1
and CDDP is an effective treatment for advanced-stage
esophageal adenocarcinoma. Recently, the effect of doce-
taxel and CDDP with docetaxel, cisplatin, 5-fluorourcil
(DCF) in the treatment of gastroesophageal cancer was
reported. The overall confirmed response rate was 37%
and median overall survival time 9.2 months. However,
grade 3 or 4 treatment-related adverse events occurred in
69% of patients on DCF therapy [9,10].
Chemotherapeutic regimens including S-1 have re-
cently produced good clinical responses and survival
benefits in patients with gastric cancer in Japan. These
positive responses were also observed in patients with
non-resectable advanced-stage gastric adenocarcinoma
[8]. The efficacy of chemotherapeutic regimens including
S-1 has also been demonstrated in cases of gastric can-
cer [16]. S-1 has many advantages, including its high ef-
ficacy, excellent tolerability, low side-effect profile, and
suitability for administration in an outpatient setting.
Furthermore, its efficacy has been demonstrated in com-
bination with CDDP for stage IV gastric adenocarcinoma
[13] and in neoadjuvant chemotherapy with CDDP for
unresectable advanced-stage gastric cancer [14,17]. To
our knowledge, however, the effectiveness of chemother-
apy with S-1 and CDDP against esophageal adenocarcin-
oma has not been previously studied. Given the positive
response of other tumors, we decided to use this chemo-
therapy regimen in our patient with advanced-stage SDP
esophageal and gastric adenocarcinoma. There has been
a reported case of SDP esophageal squamous cell carcin-
oma and gastric adenocarcinoma in which a complete
response was obtained for esophageal carcinoma to
treatment with this regimen [18]. That case was different
from this report as the carcinoma was at an early stage
and was a squamous cell carcinoma. However, these
results suggest that chemotherapy with S-1 plus CDDP
may be effective in esophageal cancer.
Generally, the initial treatment for esophageal cancer
is either chemotherapy or surgical resection, with or
without esophageal preservation. However, esophagect-
omy results in dysphagia more commonly than does
chemotherapy [19]. Furthermore, esophagectomy is
associated with high mortality and morbidity. Even at
high-volume centers, a 5% surgical mortality rate has
been reported [20]. Therefore, chemotherapy with S-1
and CDDP may offer functional and prognostic merits
over esophagectomy in patients with advanced-stage
esophageal adenocarcinoma.Conclusion
This case confirms the potential for a complete response
to S-1 and CDDP chemotherapy in patients with
advanced-stage SDP esophageal and gastric adenocarcin-
oma. The accumulation of further such cases may en-
hance our understanding of this phenomenon and lead
to the development of new treatment strategies for
advanced-stage esophageal adenocarcinoma.
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